Ayermate en es it fr

Ayermate Brand names, Ayermate Analogs

Ayermate Brand Names Mixture

  • No information avaliable

Ayermate Chemical_Formula

C20H23NS

Ayermate RX_link

No information avaliable

Ayermate fda sheet

Ayermate msds (material safety sheet)

Ayermate Synthesis Reference

No information avaliable

Ayermate Molecular Weight

309.469 g/mol

Ayermate Melting Point

< 25 oC

Ayermate H2O Solubility

Soluble as HCl salt

Ayermate State

Liquid

Ayermate LogP

5.7

Ayermate Dosage Forms

Tablets (oral, 1 mg)

Ayermate Indication

Used for the symptomatic treatment of parkinsonism.

Ayermate Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Ayermate Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Ayermate side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Ayermate Patient Information

Ayermate Organisms Affected

Humans and other mammals